Aneurysm treatment within 6 h versus 6–24 h after rupture in patients with subarachnoid hemorrhage
European Stroke Journal · 01.09.2023 · 8 (3) · 802-807
DOI: 10.1177/23969873231173273 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Stroke Journal, online erschienen am 01.09.2023. Verfasst von Mervyn DI Vergouwen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Subarachnoid Hemorrhage, Aneurysm, Ruptured, Tranexamic Acid, Mustelidae. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NuthsOhra.
Abstract (Originalsprache)
Background
The risk of rebleeding after aneurysmal subarachnoid hemorrhage (aSAH) is the highest during the initial hours after rupture. Emergency aneurysm treatment may decrease this risk, but is a logistic challenge and economic burden. We aimed to investigate whether aneurysm treatment <6 h after rupture is associated with a decreased risk of poor functional outcome compared to aneurysm treatment 6–24 h after rupture.
Methods
We used data of patients included in the ULTRA trial (NCT02684812). All patients in ULTRA were admitted within 24 h after aneurysm rupture. For the current study, we excluded patients in whom the aneurysm was not treated <24 h after rupture. We calculated crude and adjusted risk ratios (aRR) with 95% confidence intervals using Poisson regression analyses for poor functional outcome (death or dependency, assessed by the modified Rankin Scale) after aneurysm treatment <6 h versus 6–24 h after rupture. Adjustments were made for age, sex, clinical condition on admission (WFNS scale), amount of extravasated blood (Fisher score), aneurysm location, tranexamic acid treatment, and aneurysm treatment modality.
Results
We included 497 patients. Poor outcome occurred in 63/110 (57%) patients treated within 6 h compared to 145/387 (37%) patients treated 6–24 h after rupture (crude RR: 1.53, 95% CI: 1.24–1.88; adjusted RR: 1.36, 95% CI: 1.11–1.66).
Conclusion
Aneurysm treatment <6 h is not associated with better functional outcome than aneurysm treatment 6–24 h after rupture. Our results do not support a strategy aiming to treat every patient with a ruptured aneurysm <6 h after rupture.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
- Department of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.
- Department of Neurosurgery, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
- Amsterdam Neuroscience, Neurovascular Disorders, Amsterdam, The Netherlands.
ORCID-Profile: Mervyn DI Vergouwen
Förderung
- NuthsOhra
Zitieren
APA
Vergouwen, M. D., Germans, M. R., Post, R., Tjerkstra, M. A., Coert, B. A., Rinkel, G. J., Peter Vandertop, W., & Verbaan, D. (2023). Aneurysm treatment within 6 h versus 6–24 h after rupture in patients with subarachnoid hemorrhage. European Stroke Journal, 8(3), 802-807. https://doi.org/10.1177/23969873231173273
Vancouver
Vergouwen MD, Germans MR, Post R, Tjerkstra MA, Coert BA, Rinkel GJ, et al. Aneurysm treatment within 6 h versus 6–24 h after rupture in patients with subarachnoid hemorrhage. European Stroke Journal. 2023;8(3):802-807. doi:10.1177/23969873231173273
BibTeX
@article{Vergouwen2023,
author = {Vergouwen, Mervyn DI and Germans, Menno R and Post, René and Tjerkstra, Maud A and Coert, Bert A and Rinkel, Gabriel Je and Peter Vandertop, William and Verbaan, Dagmar},
title = {Aneurysm treatment within 6 h versus 6–24 h after rupture in patients with subarachnoid hemorrhage},
journal = {European Stroke Journal},
year = {2023},
volume = {8},
number = {3},
pages = {802--807},
doi = {10.1177/23969873231173273}
}
EUVIMED